¼¼°èÀÇ Àü¸³¼±¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå, ±Ô¸ð, Á¡À¯À², »ê¾÷ ºÐ¼® º¸°í¼ : À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ¿¹Ãø(2025-2034³â)
Prostate Cancer Biomarker Market Size, Share, & Industry Analysis Report: By Type (Genetic Biomarkers, Protein Biomarkers, Cell-Based Biomarkers, and Metabolomic Biomarkers), By Application, By End Use, and By Region - Market Forecast, 2025-2034
»óǰÄÚµå
:
1762314
¸®¼Ä¡»ç
:
Polaris Market Research
¹ßÇàÀÏ
:
2025³â 05¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 129 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é, Àü¸³¼±¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ±Ô¸ð´Â 2034³â±îÁö 155¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼´Â ÇöÀç ½ÃÀå ¿ªÇп¡ ´ëÇÑ »ó¼¼ÇÑ ÅëÂû·Â°ú ÇâÈÄ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.
Àü¸³¼±¾Ï ¹ÙÀÌ¿À¸¶Ä¿´Â Àü¸³¼±¾ÏÀÇ Á¸Àç, º´±â, ÁøÇàÀ» È®ÀÎÇÏ´Â µ¥ µµ¿òÀÌ µÇ´Â ü¾× ¹× Á¶Á÷ À¯·¡ÀÇ ºÐÀÚ ÁöÇ¥ÀÔ´Ï´Ù. À¯ÀüüÇÐ, ´Ü¹éÁúüÇÐ, ´ë»çüÇп¡¼ AI¿Í °°Àº ¸ÖƼ¿À¹Í½º Á¢±Ù¹ýÀÇ ÅëÇÕÀ¸·Î Áø´Ü Á¤È®µµ Çâ»ó°ú Áúº´ °èÃþȰ¡ ÁøÇàµÇ¾î ½ÃÀå ¼ö¿ä¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±¤¹üÀ§ÇÑ ÇÁ·ÎÆÄÀϸµ ±â¼úÀº ´õ ³ôÀº ¹Î°¨µµ¿Í ƯÀ̼ºÀ» °¡Áø »õ·Î¿î ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ¹ß°ßÀ» °¡´ÉÇÏ°Ô Çϰí, º¸´Ù Á¤È®ÇÑ È¯ÀÚ ºÐ·ù¿Í ¸ÂÃãÇü Ä¡·á Àü·«À» Áö¿øÇÕ´Ï´Ù. ¸ÖƼ¿À¹Í½º ±â¹Ý ¹ÙÀÌ¿À¸¶Ä¿ Ç÷§ÆûÀÇ Ã¤ÅÃÀº ¸ÂÃãÇü ¾Ï Ä¡·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼ ÀÓ»ó ¹× ¿¬±¸ ºÐ¾ß¿¡¼ Á¡Á¡ ´õ Áß½ÉÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.
ºñħ½ÀÀû, Àúħ½ÀÀû Áø´Ü ±â¼úÀÇ ¹ßÀüÀÌ ½ÃÀå °³Ã´À» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¾×ü »ý°ËÀº Ç÷¾×À̳ª ¼Òº¯ »ùÇÃÀ» ÅëÇØ Àü¸³¼±¾ÏÀ» °¨ÁöÇÏ°í ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ´Ù´Â Á¡¿¡¼ ±âÁ¸ÀÇ Á¶Á÷ »ý°ËÀ» ´ëüÇÒ ¼ö ÀÖ´Â º¸´Ù ¾ÈÀüÇÏ°í Æí¸®ÇÑ ¹æ¹ýÀ¸·Î °¢±¤¹Þ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹æ¹ýÀº ȯÀÚÀÇ ¼øÀÀµµ¸¦ Çâ»ó½Ã۰í, ½Ç½Ã°£ Áúº´ ¸ð´ÏÅ͸µ°ú Ä¡·á¹ý Á¶Á¤À» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÀÇ·á ½Ã½ºÅÛÀÌ Á¶±â ¹ß°ß°ú ´ú ħ½ÀÀûÀÎ Áø´ÜÀ» ¿ì¼±½ÃÇÔ¿¡ µû¶ó ÀÌ·¯ÇÑ Çõ½Å ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä´Â Áö¼ÓÀûÀ¸·Î Áõ°¡Çϰí ÀÖÀ¸¸ç, Àü¸³¼±¾Ï °ü¸®ÀÇ Çõ½Å¿¡ ÀÖ¾î ÷´Ü ¹ÙÀÌ¿À¸¶Ä¿ ±â¼úÀÇ ¿ªÇÒÀÌ °ÈµÇ°í ÀÖ½À´Ï´Ù.
Àü¸³¼±¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå º¸°í¼ - ÁÖ¿ä ³»¿ë
À¯Çüº°·Î´Â ´Ü¹éÁú ¹ÙÀÌ¿À¸¶Ä¿ ºÐ¾ß°¡ 2024³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇßÀ¸¸ç, ÀÌ´Â ±¤¹üÀ§ÇÑ ÀÓ»ó Àû¿ë°ú ¿©·¯ ´Ü°èÀÇ Áúº´ °ü¸® ´Ü°è¿¡ °ÉÃÄ È®¸³µÈ °ËÁõÀ» µÞ¹ÞħÇÏ´Â °ÍÀ¸·Î ºÐ¼®µÆ½À´Ï´Ù.
¿ëµµº°·Î´Â °³ÀθÂÃãÇü Ä¡·á Á¢±Ù¹ý°ú Á¤¹ÐÄ¡·áÀÇ µµÀÔÀÌ È®´ëµÊ¿¡ µû¶ó µ¿¹ÝÁø´Ü ºÐ¾ß°¡ °¡Àå ºü¸£°Ô È®´ëµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
2024³â ºÏ¹Ì´Â Àü¸³¼±¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå¿¡¼ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» À¯ÁöÇߴµ¥, ÀÌ´Â Á¤±³ÇÑ ÀÇ·á ½Ã½ºÅÛ, Áúº´¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, Áø´Ü ¹× ¹ÙÀÌ¿À Á¦¾à ±â¾÷ÀÇ ÁýÀû¿¡ ±âÀÎÇÕ´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀåÀº ÇコÄɾî Áö½ÄÀÇ Çâ»ó, Áø´Ü ´É·Â ½ÃÀå °³Ã´, ½ÅÈï±¹ÀÇ ¾Ï ¹ßº´·ü Áõ°¡¿¡ ÈûÀÔ¾î ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ½ÃÀå ¼ºÀåÀ» ´Þ¼ºÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
ÁÖ¿ä ¼¼°è ±â¾÷À¸·Î´Â Arquer Diagnostics, Beckman Coulter, Bio-Techne, DiaCarta, Exact Sciences Corporation, ExoDx, Genomic Health, GenPath, Oncology, MDxHealth, Myriad Genetics, Nucleix, OPKO Health, Proteomedix, Veracyte Oncology, MDxHealth, Myriad Genetics, Nucleix, OPKO Health, Proteomedix, Veracyte µîÀÌ ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼·Ð
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå Á¶»ç ¹æ¹ý
Á¦4Àå ¼¼°èÀÇ Àü¸³¼±¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ÀλçÀÌÆ®
- ½ÃÀå ÇöȲ
- Àü¸³¼±¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ¿ªÇÐ
- ¼ºÀå ÃËÁø¿äÀΰú ±âȸ
- ¼ºÀå ¾ïÁ¦¿äÀΰú °úÁ¦
- ¿©·Ð°ú ÇÁ¶óÀ̹ö½Ã¿¡ °üÇÑ ÆÇ·Ê
- PESTEL ºÐ¼®
- Àü¸³¼±¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå µ¿Çâ
- ¹ë·ùüÀÎ ºÐ¼®
Á¦5Àå ¼¼°èÀÇ Àü¸³¼±¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : À¯Çüº°
- ÁÖ¿ä Á¶»ç °á°ú
- ¼·Ð
- À¯ÀüÀÚ ¹ÙÀÌ¿À¸¶Ä¿
- ´Ü¹éÁú ¹ÙÀÌ¿À¸¶Ä¿
- ¼¼Æ÷ ±â¹Ý ¹ÙÀÌ¿À¸¶Ä¿
- ´ë»çüÇÐ ¹ÙÀÌ¿À¸¶Ä¿
Á¦6Àå ¼¼°èÀÇ Àü¸³¼±¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : ¿ëµµº°
- ÁÖ¿ä Á¶»ç °á°ú
- ¼·Ð
- ½ºÅ©¸®´× ¹× Á¶±â ¹ß°ß
- Áø´Ü ¹× ¸®½ºÅ© °èÃþÈ
- ¿¹ÈÄ ¹× Ä¡·á ¸ð´ÏÅ͸µ
- µ¿¹ÝÁø´Ü
Á¦7Àå ¼¼°èÀÇ Àü¸³¼±¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : ÃÖÁ¾ ¿ëµµº°
- ÁÖ¿ä Á¶»ç °á°ú
- ¼·Ð
- º´¿ø ¹× Áø´Ü½ÇÇè½Ç
- Çмú¿¬±¸±â°ü
- ¹ÙÀÌ¿ÀÀǾàǰ ±â¾÷
Á¦8Àå ¼¼°èÀÇ Àü¸³¼±¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : Áö¿ªº°
- ÁÖ¿ä Á¶»ç °á°ú
- ¼·Ð
- Àü¸³¼±¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ºÐ¼® : Áö¿ªº°, 2020-2034³â
- ºÏ¹Ì
- ºÏ¹Ì : À¯Çüº°, 2020-2034³â
- ºÏ¹Ì : ¿ëµµº°, 2020-2034³â
- ºÏ¹Ì : ÃÖÁ¾ ¿ëµµº°, 2020-2034³â
- ¹Ì±¹
- ij³ª´Ù
- À¯·´
- À¯·´ : À¯Çüº°, 2020-2034³â
- À¯·´ : ¿ëµµº°, 2020-2034³â
- À¯·´ : ÃÖÁ¾ ¿ëµµº°, 2020-2034³â
- ¿µ±¹
- ÇÁ¶û½º
- µ¶ÀÏ
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ³×´ú¶õµå
- ·¯½Ã¾Æ
- ±âŸ À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¾Æ½Ã¾ÆÅÂÆò¾ç : À¯Çüº°, 2020-2034³â
- ¾Æ½Ã¾ÆÅÂÆò¾ç : ¿ëµµº°, 2020-2034³â
- ¾Æ½Ã¾ÆÅÂÆò¾ç : ÃÖÁ¾ ¿ëµµº°, 2020-2034³â
- Áß±¹
- Àεµ
- ¸»·¹À̽þÆ
- ÀϺ»
- Àεµ³×½Ã¾Æ
- Çѱ¹
- È£ÁÖ
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : À¯Çüº°, 2020-2034³â
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ¿ëµµº°, 2020-2034³â
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ÃÖÁ¾ ¿ëµµº°, 2020-2034³â
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
- À̽º¶ó¿¤
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- ¶óƾ¾Æ¸Þ¸®Ä«
- ¶óƾ¾Æ¸Þ¸®Ä« : À¯Çüº°, 2020-2034³â
- ¶óƾ¾Æ¸Þ¸®Ä« : ¿ëµµº°, 2020-2034³â
- ¶óƾ¾Æ¸Þ¸®Ä« : ÃÖÁ¾ ¿ëµµº°, 2020-2034³â
- ¸ß½ÃÄÚ
- ºê¶óÁú
- ¾Æ¸£ÇîÆ¼³ª
- ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
Á¦9Àå °æÀï ±¸µµ
- È®´ë¿Í Àμö ºÐ¼®
- Á¦ÈÞ/Çù¾÷/ÇÕÀÇ/°ø°³
Á¦10Àå ±â¾÷ °³¿ä
- AlterG, Inc.
- Biodex Medical Systems, Inc.
- Caremax Prostate Cancer Biomarker Ltd.
- DJO Global
- Drive DeVilbiss Healthcare
- Ekso Bionics
- GF Health Products, Inc.
- Hocoma AG
- Hospital Equipment Mfg. Co
- Invacare Corporation
- Maddak, Inc.
- Ottobock
- Patterson Medical(now Ability Dynamics)
- Rifton Equipment
- TheraBand(Performance Health)
LSH
¿µ¹® ¸ñÂ÷
The prostate cancer biomarkers market size is expected to reach USD 15.58 billion by 2034, according to a new study by Polaris Market Research. The report "Prostate Cancer Biomarker Market Share, Size, & Industry Analysis Report: By Type (Genetic Biomarkers, Protein Biomarkers, Cell-Based Biomarkers, and Metabolomic Biomarkers), By application, By End Use, and By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Prostate cancer biomarkers are molecular indicators derived from bodily fluids or tissues that aid in identifying the presence, stage, or progression of prostate cancer. The integration of multi-omics approaches such as AI in genomics, proteomics, and metabolomics to improve diagnostic precision and disease stratification further boosts the market demand. These wide profiling techniques allow the discovery of novel biomarkers with greater sensitivity and specificity, supporting more accurate patient categorization and tailored treatment strategies. The adoption of multi-omics-driven biomarker platforms is becoming increasingly central to clinical and research settings as the focus on individualized cancer care intensifies.
The advancement of noninvasive and minimally invasive diagnostic techniques is boosting the market development. Liquid biopsies are gaining traction for their ability to detect and monitor prostate cancer using blood or urine samples, offering a safer and more convenient alternative to traditional tissue biopsies. These methods improve patient compliance and allow for real-time disease monitoring and therapy adjustment. The demand for such innovations continues to grow as healthcare systems prioritize early detection and less invasive diagnostics, reinforcing the role of advanced biomarker technologies in transforming prostate cancer management.
Prostate Cancer Biomarker Market Report Highlights
In terms of type, the protein biomarkers segment accounted for the largest market share in 2024, supported by their extensive clinical applications and well-established validation across multiple disease management phases.
Based on application, the companion diagnostics segment is anticipated to experience the most rapid expansion, propelled by growing implementation of personalized treatment approaches and precision therapies.
In 2024, North America maintained the largest revenue share of the prostate cancer biomarker market, owing to its sophisticated healthcare systems, elevated disease awareness, and concentration of diagnostic and biopharmaceutical firms.
The Asia Pacific market is projected to achieve the fastest market growth during the forecast period, driven by improving healthcare knowledge, developing diagnostic capabilities, and increasing cancer prevalence in emerging nations.
A few global key market players include Arquer Diagnostics; Beckman Coulter, Inc.; Bio-Techne; DiaCarta; Exact Sciences Corporation; ExoDx; Genomic Health; GenPath Oncology; MDxHealth; Myriad Genetics, Inc.; Nucleix; OPKO Health, Inc.; Proteomedix; and Veracyte, Inc.
Polaris Market Research has segmented the prostate cancer biomarker market report on the basis of type, application, end use, and region:
By Type Outlook (Revenue, USD Billion, 2020-2034)
Genetic Biomarkers
Protein Biomarkers
Cell-based Biomarkers
Metabolomic Biomarkers
By Application Outlook (Revenue, USD Billion, 2020-2034)
Screening and Early Detection
Diagnosis and Risk Stratification
Prognosis and Treatment Monitoring
Companion Diagnostics
By End Use Outlook (Revenue, USD Billion, 2020-2034)
Hospitals & Diagnostic Laboratories
Academic & Research Institutes
Biopharmaceutical Companies
By Regional Outlook (Revenue, USD Billion, 2020-2034)
North America
US
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Vietnam
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
3. Research Methodology
- 3.1. Overview
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Prostate Cancer Biomarker Market Insights
- 4.1. Prostate Cancer Biomarker Market - Market Snapshot
- 4.2. Prostate Cancer Biomarker Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Rising Prevalence of Prostate Cancer and Aging Populations
- 4.2.1.2. Advancements in Biomarker Technologies
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High Cost of Biomarker Development and Testing
- 4.2.3. Public opinion and privacy legal precedents
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Prostate Cancer Biomarker Market Trends
- 4.6. Value Chain Analysis
5. Global Prostate Cancer Biomarker Market, by Type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 5.3. Genetic Biomarkers
- 5.3.1. Global Prostate Cancer Biomarker Market, by Genetic Biomarkers, by Region, 2020-2034 (USD Billion)
- 5.4. Protein Biomarkers
- 5.4.1. Global Prostate Cancer Biomarker Market, by Protein Biomarkers, by Region, 2020-2034 (USD Billion)
- 5.5. Cell-based Biomarkers
- 5.5.1. Global Prostate Cancer Biomarker Market, by Cell-based Biomarkers, by Region, 2020-2034 (USD Billion)
- 5.6. Metabolomic Biomarkers
- 5.6.1. Global Prostate Cancer Biomarker Market, by Metabolomic Biomarkers, by Region, 2020-2034 (USD Billion)
6. Global Prostate Cancer Biomarker Market, by Application
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 6.3. Screening and Early Detection
- 6.3.1. Global Prostate Cancer Biomarker Market, by Screening and Early Detection, by Region, 2020-2034 (USD Billion)
- 6.4. Diagnosis and Risk Stratification
- 6.4.1. Global Prostate Cancer Biomarker Market, by Diagnosis and Risk Stratification, by Region, 2020-2034 (USD Billion)
- 6.5. Prognosis and Treatment Monitoring
- 6.5.1. Global Prostate Cancer Biomarker Market, by B-Arrestin Functional Assays, by Region, 2020-2034 (USD Billion)
- 6.6. Companion Diagnostics
- 6.6.1. Global Prostate Cancer Biomarker Market, by Companion Diagnostics, by Region, 2020-2034 (USD Billion)
7. Global Prostate Cancer Biomarker Market, by End Use
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 7.3. Hospitals & Diagnostic Laboratories
- 7.3.1. Global Prostate Cancer Biomarker Market, by Hospitals & Diagnostic Laboratories, by Region, 2020-2034 (USD Billion)
- 7.4. Academic & Research Institutes
- 7.4.1. Global Prostate Cancer Biomarker Market, by Academic & Research Institutes, by Region, 2020-2034 (USD Billion)
- 7.5. Biopharmaceutical Companies
- 7.5.1. Global Prostate Cancer Biomarker Market, by Biopharmaceutical Companies, by Region, 2020-2034 (USD Billion)
8. Global Prostate Cancer Biomarker Market, by Geography
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Prostate Cancer Biomarker Market Assessment, By Geography, 2020-2034 (USD Billion)
- 8.3. Prostate Cancer Biomarker Market - North America
- 8.3.1. North America: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.3.2. North America: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.3.3. North America: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.3.4. Prostate Cancer Biomarker Market - US
- 8.3.4.1. US: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.3.4.2. US: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.3.4.3. US: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.3.5. Prostate Cancer Biomarker Market - Canada
- 8.3.5.1. Canada: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.3.5.2. Canada: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.3.5.3. Canada: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.4. Prostate Cancer Biomarker Market - Europe
- 8.4.1. Europe: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.4.2. Europe: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.4.3. Europe: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.4.4. Prostate Cancer Biomarker Market - UK
- 8.4.4.1. UK: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.4.4.2. UK: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.4.4.3. UK: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.4.5. Prostate Cancer Biomarker Market - France
- 8.4.5.1. France: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.4.5.2. France: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.4.5.3. France: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.4.6. Prostate Cancer Biomarker Market - Germany
- 8.4.6.1. Germany: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.4.6.2. Germany: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.4.6.3. Germany: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.4.7. Prostate Cancer Biomarker Market - Italy
- 8.4.7.1. Italy: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.4.7.2. Italy: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.4.7.3. Italy: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.4.8. Prostate Cancer Biomarker Market - Spain
- 8.4.8.1. Spain: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.4.8.2. Spain: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.4.8.3. Spain: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.4.9. Prostate Cancer Biomarker Market - Netherlands
- 8.4.9.1. Netherlands: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.4.9.2. Netherlands: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.4.9.3. Netherlands: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.4.10. Prostate Cancer Biomarker Market - Russia
- 8.4.10.1. Russia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.4.10.2. Russia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.4.10.3. Russia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.4.11. Prostate Cancer Biomarker Market - Rest of Europe
- 8.4.11.1. Rest of Europe: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.4.11.2. Rest of Europe: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.4.11.3. Rest of Europe: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.5. Prostate Cancer Biomarker Market - Asia Pacific
- 8.5.1. Asia Pacific: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.5.2. Asia Pacific: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.5.3. Asia Pacific: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.5.4. Prostate Cancer Biomarker Market - China
- 8.5.4.1. China: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.5.4.2. China: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.5.4.3. China: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.5.5. Prostate Cancer Biomarker Market - India
- 8.5.5.1. India: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.5.5.2. India: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.5.5.3. India: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.5.6. Prostate Cancer Biomarker Market - Malaysia
- 8.5.6.1. Malaysia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.5.6.2. Malaysia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.5.6.3. Malaysia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.5.7. Prostate Cancer Biomarker Market - Japan
- 8.5.7.1. Japan: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.5.7.2. Japan: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.5.7.3. Japan: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.5.8. Prostate Cancer Biomarker Market - Indonesia
- 8.5.8.1. Indonesia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.5.8.2. Indonesia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.5.8.3. Indonesia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.5.9. Prostate Cancer Biomarker Market - South Korea
- 8.5.9.1. South Korea: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.5.9.2. South Korea: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.5.9.3. South Korea: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.5.10. Prostate Cancer Biomarker Market - Australia
- 8.5.10.1. Australia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.5.10.2. Australia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.5.10.3. Australia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.5.11. Prostate Cancer Biomarker Market - Rest of Asia Pacific
- 8.5.11.1. Rest of Asia Pacific: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.5.11.2. Rest of Asia Pacific: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.5.11.3. Rest of Asia Pacific: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.6. Prostate Cancer Biomarker Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.6.2. Middle East & Africa: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.6.3. Middle East & Africa: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.6.4. Prostate Cancer Biomarker Market - Saudi Arabia
- 8.6.4.1. Saudi Arabia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.6.4.2. Saudi Arabia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.6.4.3. Saudi Arabia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.6.5. Prostate Cancer Biomarker Market - UAE
- 8.6.5.1. UAE: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.6.5.2. UAE: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.6.5.3. UAE: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.6.6. Prostate Cancer Biomarker Market - Israel
- 8.6.6.1. Israel: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.6.6.2. Israel: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.6.6.3. Israel: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.6.7. Prostate Cancer Biomarker Market - South Africa
- 8.6.7.1. South Africa: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.6.7.2. South Africa: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.6.7.3. South Africa: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.6.8. Prostate Cancer Biomarker Market - Rest of Middle East & Africa
- 8.6.8.1. Rest of Middle East & Africa: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.6.8.2. Rest of Middle East & Africa: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.6.8.3. Rest of Middle East & Africa: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.7. Prostate Cancer Biomarker Market - Latin America
- 8.7.1. Latin America: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.7.2. Latin America: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.7.3. Latin America: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.7.4. Prostate Cancer Biomarker Market - Mexico
- 8.7.4.1. Mexico: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.7.4.2. Mexico: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.7.4.3. Mexico: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.7.5. Prostate Cancer Biomarker Market - Brazil
- 8.7.5.1. Brazil: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.7.5.2. Brazil: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.7.5.3. Brazil: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.7.6. Prostate Cancer Biomarker Market - Argentina
- 8.7.6.1. Argentina: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.7.6.2. Argentina: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.7.6.3. Argentina: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.7.7. Prostate Cancer Biomarker Market - Rest of Latin America
- 8.7.7.1. Rest of Latin America: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.7.7.2. Rest of Latin America: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.7.7.3. Rest of Latin America: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. AlterG, Inc.
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Biodex Medical Systems, Inc.
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Caremax Prostate Cancer Biomarker Ltd.
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. DJO Global
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. Drive DeVilbiss Healthcare
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Ekso Bionics
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. GF Health Products, Inc.
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Hocoma AG
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Hospital Equipment Mfg. Co
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Invacare Corporation
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
- 10.11. Maddak, Inc.
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Benchmarking
- 10.11.4. Recent Development
- 10.12. Ottobock
- 10.12.1. Company Overview
- 10.12.2. Financial Performance
- 10.12.3. Product Benchmarking
- 10.12.4. Recent Development
- 10.13. Patterson Medical (now Ability Dynamics)
- 10.13.1. Company Overview
- 10.13.2. Financial Performance
- 10.13.3. Product Benchmarking
- 10.13.4. Recent Development
- 10.14. Rifton Equipment
- 10.14.1. Company Overview
- 10.14.2. Financial Performance
- 10.14.3. Product Benchmarking
- 10.14.4. Recent Development
- 10.15. TheraBand (Performance Health)
- 10.15.1. Company Overview
- 10.15.2. Financial Performance
- 10.15.3. Product Benchmarking
- 10.15.4. Recent Development
°ü·ÃÀÚ·á